The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.
After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...
The latest update is out from Nektar Therapeutics ( (NKTR) ).
Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...
Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...
Fintel reports that on November 4, 2024, Piper Sandler initiated coverage of Nektar Therapeutics (NasdaqCM:NKTR) with a ...
California, USA-based biotech Nektar Therapeutics’ (Nasdaq: NKTR) shares closed up more than 8% at $1.33 yesterday after it ...
Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...
Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:NKTR), citing the company’s lead asset ...
On Monday, Nektar Therapeutics (NKTR) stock saw a modest uptick, ending the day at $1.33 which represents a slight increase of $0.10 or 8.13% from the prior close of $1.23. The stock opened at $1.37 ...
On Wednesday, Nektar Therapeutics (NKTR) stock saw a decline, ending the day at $1.41 which represents a decrease of $-0.03 or -2.08% from the prior close of $1.44. The stock opened at $1.44 and ...
Shares of Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) have been given an average rating of “Hold” by the six brokerages that are currently covering the stock, Marketbeat Ratings reports.